Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1973 Jan;52(1):32–38. doi: 10.1172/JCI107171

Interchange of Apolipoproteins between Chylomicrons and High Density Lipoproteins during Alimentary Lipemia in Man

Richard J Havel 1, John P Kane 1, Moti L Kashyap 1
PMCID: PMC302224  PMID: 4345202

Abstract

Apolipoproteins of the “C” group in human blood plasma, which contain the activator of the lipoprotein lipase-substrate interaction, were found to be transferred specifically from serum to phospholipid-stabilized fat emulsion. Content and distribution of apoprotein activator were measured in healthy men in the postabsorptive state and 4 h after ingestion of meals containing 100 g fat. Content of activator protein in whole serum did not change after ingestion of the fat-rich meals but that contained in triglyceride-rich lipoproteins of density (d) <1.006 approximately doubled whereas that of high density lipoproteins fell by half. The increased activator content of triglyceride-rich lipoproteins was virtually confined to chylomicrons and its concentration in chylomicron apoprotein was substantially greater than that in very low density lipoproteins. This difference could be ascribed largely to a higher content of C apoproteins in chylomicron protein since both the concentration of C apoproteins and of apoprotein activator were directly proportional to particle diameter while the pattern of fast-migrating C apoproteins in polyacrylamide gels was similar among chylomicrons and subfractions of very low density lipoproteins. Apparent concentration of activator protein was much greater in the high density lipoprotein subfraction of d 1.063-1.125 than in the subfraction of d 1.125-1.21. In the subfraction of d 1.063-1.125, the concentration of activator protein and of fast-migrating C apoproteins in polyacrylamide gels decreased after the fat-rich meal. Concentration of phospholipids in this fraction increased gradually to a peak 43% above the basal value 6 h after the meal. The results obtained demonstrate that high density lipoproteins contribute certain functionally important polar constituents to chylomicrons during alimentary lipemia in man and suggest that they also receive surface constituents from chylomicrons during the course of their metabolism.

Full text

PDF

Images in this article

34Image
on p.34
34Image
on p.34
35Image
on p.35

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BRAGDON J. H., HAVEL R. J., BOYLE E. Human serum lipoproteins. I. Chemical composition of four fractions. J Lab Clin Med. 1956 Jul;48(1):36–42. [PubMed] [Google Scholar]
  2. Bergman E. N., Havel R. J., Wolfe B. M., Bohmer T. Quantitative studies of the metabolism of chylomicron triglycerides and cholesterol by liver and extrahepatic tissues of sheep and dogs. J Clin Invest. 1971 Sep;50(9):1831–1839. doi: 10.1172/JCI106674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bier D. M., Havel R. J. Activation of lipoprotein lipase by lipoprotein fractions of human serum. J Lipid Res. 1970 Nov;11(6):565–570. [PubMed] [Google Scholar]
  4. Bilheimer D. W., Eisenberg S., Levy R. I. The metabolism of very low density lipoprotein proteins. I. Preliminary in vitro and in vivo observations. Biochim Biophys Acta. 1972 Feb 21;260(2):212–221. doi: 10.1016/0005-2760(72)90034-3. [DOI] [PubMed] [Google Scholar]
  5. Brown W. V., Baginsky M. L. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun. 1972 Jan 31;46(2):375–382. doi: 10.1016/s0006-291x(72)80149-9. [DOI] [PubMed] [Google Scholar]
  6. Eisenberg S., Bilheimer D., Lindgren F., Levy R. I. On the apoprotein composition of human plasma very low density lipoprotein subfractions. Biochim Biophys Acta. 1972 Feb 21;260(2):329–333. doi: 10.1016/0005-2760(72)90045-8. [DOI] [PubMed] [Google Scholar]
  7. Ganesan D., Bradford R. H., Alaupovic P., McConathy W. J. Differential activation of lipoprotein lipase from human post-heparin plasma, milk and adipose tissue by polypeptides of human serum Apolipoprotein C. FEBS Lett. 1971 Jun 24;15(3):205–208. doi: 10.1016/0014-5793(71)80312-5. [DOI] [PubMed] [Google Scholar]
  8. HAVEL R. J., EDER H. A., BRAGDON J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955 Sep;34(9):1345–1353. doi: 10.1172/JCI103182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. HAVEL R. J. Early effects of fat ingestion on lipids and lipoproteins of serum in man. J Clin Invest. 1957 Jun;36(6 Pt 1):848–854. doi: 10.1172/JCI103491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. HOFMANN A. F. Exchange of iodine-131-labeled chylomicron protein in vitro. Am J Physiol. 1960 Sep;199:433–436. doi: 10.1152/ajplegacy.1960.199.3.433. [DOI] [PubMed] [Google Scholar]
  11. Havel R. J., Shore V. G., Shore B., Bier D. M. Role of specific glycopeptides of human serum lipoproteins in the activation of lipoprotein lipase. Circ Res. 1970 Oct;27(4):595–600. doi: 10.1161/01.res.27.4.595. [DOI] [PubMed] [Google Scholar]
  12. KORN E. D. Clearing factor, a heparin-activated lipoprotein lipase. II. Substrate specificity and activation of coconut oil. J Biol Chem. 1955 Jul;215(1):15–26. [PubMed] [Google Scholar]
  13. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  14. LaRosa J. C., Levy R. I., Herbert P., Lux S. E., Fredrickson D. S. A specific apoprotein activator for lipoprotein lipase. Biochem Biophys Res Commun. 1970 Oct 9;41(1):57–62. doi: 10.1016/0006-291x(70)90468-7. [DOI] [PubMed] [Google Scholar]
  15. Lossow W. J., Lindgren F. T., Jensen L. C. Net uptake of rat serum protein by Sf greater than 400 lymph chylomicrons in vitro. Biochim Biophys Acta. 1967 Dec 5;144(3):670–677. doi: 10.1016/0005-2760(67)90056-2. [DOI] [PubMed] [Google Scholar]
  16. MINARI O., ZILVERSMIT D. B. BEHAVIOR OF DOG LYMPH CHYLOMICRON LIPID CONSTITUENTS DURING INCUBATION WITH SERUM. J Lipid Res. 1963 Oct;4:424–436. [PubMed] [Google Scholar]
  17. NESTEL P. J., HAVEL R. J., BEZMAN A. METABOLISM OF CONSTITUENT LIPIDS OF DOG CHYLOMICRONS. J Clin Invest. 1963 Aug;42:1313–1321. doi: 10.1172/JCI104815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. NICHOLS A. V., SMITH L. EFFECT OF VERY LOW-DENSITY LIPOPROTEINS ON LIPID TRANSFER IN INCUBATED SERUM. J Lipid Res. 1965 Apr;6:206–210. [PubMed] [Google Scholar]
  19. Nichols A. V. Human serum lipoproteins and their interrelationships. Adv Biol Med Phys. 1967;11:109–158. doi: 10.1016/b978-1-4832-3107-5.50008-x. [DOI] [PubMed] [Google Scholar]
  20. Redgrave T. G. Formation of cholesteryl ester-rich particulate lipid during metabolism of chylomicrons. J Clin Invest. 1970 Mar;49(3):465–471. doi: 10.1172/JCI106255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Sata T., Estrich D. L., Wood P. D., Kinsell L. W. Evaluation of gel chromatography for plasma lipoprotein fractionation. J Lipid Res. 1970 Jul;11(4):331–340. [PubMed] [Google Scholar]
  22. Sata T., Havel R. J., Jones A. L. Characterization of subfractions of triglyceride-rich lipoproteins separated by gel chromatography from blood plasma of normolipemic and hyperlipemic humans. J Lipid Res. 1972 Nov;13(6):757–768. [PubMed] [Google Scholar]
  23. Scanu A. Binding of human serum high density lipoprotein apoprotein with aqueous dispersions of phospholipids. J Biol Chem. 1967 Feb 25;242(4):711–719. [PubMed] [Google Scholar]
  24. Stewart C. P., Hendry E. B. The phospholipins of blood. Biochem J. 1935 Jul;29(7):1683–1689. doi: 10.1042/bj0291683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. ZAK B., DICKENMAN R. C., WHITE E. G., BURNETT H., CHERNEY P. J. Rapid estimation of free and total cholesterol. Am J Clin Pathol. 1954 Nov;24(11):1307–1315. doi: 10.1093/ajcp/24.11_ts.1307. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES